Lenalidomide in the treatment of chronic lymphocytic leukemia-Reference-Cited by-同舟云学术

Lenalidomide in the treatment of chronic lymphocytic leukemia

Published:2017-04-17 Issue:5 Volume:26 Page:633-650
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Itchaki Gilad¹,Brown Jennifer R.¹

Affiliation:

1. Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543784.2017.1313230

Reference151 articles.

1. National Cancer Institute. Surveillance epidemiology and end results cancer statistics review. [cited 2016 Feb 27]. Available from: http://seer.cancer.gov/statfacts/html/clyl.html. Published: National Cancer Institute. 2016.

2. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data

3. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines

4. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Maintenance low-dose fixed duration lenalidomide and rituximab following bendamustine and rituximab induction in previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma;Leukemia & Lymphoma;2024-06-10

2. Treatment of Richter’s Transformation with Novel Therapies;Current Hematologic Malignancy Reports;2024-01-09

3. Maintenance therapy for chronic lymphocytic leukaemia;Cochrane Database of Systematic Reviews;2024-01-04

4. Current Treatment Options in Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: a Review;Current Treatment Options in Oncology;2023-07-06

5. Obinutuzumab, High-Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients with Richter’s Syndrome;Cancers;2022-12-08